Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$46.75 USD

46.75
1,152,445

+0.47 (1.02%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals

by Zacks Equity Research

Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.

Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit

by Zacks Equity Research

Merck's (MRK) phase III study on Keytruda shows a statistically significant overall survival benefit for patients with stage II, IIIA or IIIB NSCLC.

Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update

by Zacks Equity Research

Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.

Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro

by Zacks Equity Research

Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.

Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study

by Zacks Equity Research

Jasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic spontaneous urticaria. The stock of the company rises 16%.

J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC

by Zacks Equity Research

J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive NSCLC.

Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion

by Zacks Equity Research

Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.

Apellis (APLS) Provides Syfovre Q3 Preliminary Revenues Guidance

by Zacks Equity Research

Apellis' (APLS) shares rise as it provides third-quarter 2023 preliminary revenues guidance for Syfovre, approved for the treatment of geographic atrophy.

AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker

by Zacks Equity Research

AbbVie's (ABBV) buyout of Mitokinin, which is making a novel treatment for Parkinson's Disease (PD), if successfully closed, is likely to strengthen its neuroscience pipeline.

Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study

by Zacks Equity Research

Lineage (LCTX) rises 10% on positive imaging analyses results from the phase I/IIa study of OpRegen in patients with geographic atrophy secondary to age-related macular degeneration.

Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin

by Zacks Equity Research

Orchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American Depositary Share, which amounts to a total transaction value of approximately $478 million. Shares rise 97%.

Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data

by Zacks Equity Research

Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for NVL-655 to treat advanced ALK-positive NSCLC.

Sanofi (SNY) Signs Deal to Co-Develop Teva's IBD Candidate

by Zacks Equity Research

Sanofi (SNY) and Teva enter into a collaboration deal to co-develop and co-commercialize the latter's inflammatory bowel disease candidate, TEV'574.

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

by Zacks Equity Research

Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why

by Zacks Equity Research

Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.

Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH

by Zacks Equity Research

Apellis (APLS) receives the FDA approval for Empaveli Injector, a self-administred on-body device, to treat patients with paroxysmal nocturnal hemoglobinuria.

NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up

by Zacks Equity Research

NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.

Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection

by Zacks Equity Research

Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

by Zacks Equity Research

Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.

Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%

by Zacks Equity Research

Bionomics (BNOX) announces positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder. The stock of the company rallies 244%.

MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why

by Zacks Equity Research

Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

by Zacks Equity Research

Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.

Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug

by Zacks Equity Research

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.

Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock

by Zacks Equity Research

Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.